No data to show
XNAS
ERAS
Market cap396mUSD
Aug 04, Last price
1.40USD
1D
0.72%
1Q
12.00%
IPO
-92.19%
Name
Erasca Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
81.43%
Rev. gr., 5y
%
Revenues
0k
Net income
-162m
L+29.28%
CFO
-109m
L+8.10%
Profile
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 157,087 | 145,257 | 148,091 | |||
Unusual Expense (Income) | ||||||
NOPBT | (157,087) | (145,257) | (148,091) | |||
NOPBT Margin | ||||||
Operating Taxes | (4,645) | |||||
Tax Rate | ||||||
NOPAT | (157,087) | (145,257) | (143,446) | |||
Net income | (161,650) 29.28% | (125,042) -47.50% | (238,160) 58.68% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 239,861 | 2,085 | 98,895 | |||
BB yield | -4.09% | -0.65% | -18.80% | |||
| Debt | ||||||
Debt current | 4,619 | 7,940 | 1,305 | |||
Long-term debt | 99,159 | 107,748 | 108,891 | |||
Deferred revenue | ||||||
Other long-term liabilities | 362 | 566 | 573 | |||
Net debt | (194,531) | (206,712) | (325,832) | |||
| Cash flow | ||||||
Cash from operating activities | (109,417) | (101,217) | (103,264) | |||
CAPEX | (60) | (1,775) | (16,551) | |||
Cash from investing activities | (156,616) | (91,220) | (71,081) | |||
Cash from financing activities | 240,697 | 1,295 | 98,075 | |||
FCF | (145,438) | (140,212) | (175,369) | |||
| Balance | ||||||
Cash | 298,309 | 312,350 | 435,620 | |||
Long term investments | 10,050 | 408 | ||||
Excess cash | 298,309 | 322,400 | 436,028 | |||
Stockholders' equity | (767,230) | (605,921) | (481,997) | |||
Invested Capital | 1,242,980 | 983,002 | 56,697 | |||
ROIC | 67.38% | |||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 2,338,179 | 150,185 | 122,025 | |||
Price | 2.51 17.84% | 2.13 -50.58% | 4.31 -72.34% | |||
Market cap | 5,868,830 1,734.62% | 319,894 -39.18% | 525,927 -71.66% | |||
EV | 5,674,299 | 113,182 | 200,095 | |||
EBITDA | (153,282) | (141,525) | (145,450) | |||
EV/EBITDA | ||||||
Interest | 201,359 | |||||
Interest/NOPBT | ||||||